The rule of 1.roma can make the detection rate of ovarian cancer reach 90%. Many tumor markers, such as CA 125. He has his own advantages in diagnosis. The latest research shows that the combined screening and comprehensive evaluation of risk factors such as age and region are adopted. Recently, the first prospective, double-blind, multicenter study of Abbott's ovarian cancer risk determination rules based on China population has been completed.
2. Rome rule can judge the risk of ovarian cancer more accurately. The marker CA 125 is the most widely used biomarker in ovarian cancer, and it is a classic marker for clinical diagnosis of ovarian cancer. However, there are also many shortcomings, such as only 50% of patients' CA 125 level is increased, which is not specific enough, easily disturbed by benign diseases, and has low sensitivity to early judgment of ovarian cancer, which is affected by menopause or not.
The purpose of Rome index calculation is to improve the sensitivity and specificity of HE4 and CA 12-5. Rome index reduced the false positive rate of CA 12-5 and improved the specificity of CA 12-5. The assessment of CA 12-5 and HE4 can learn from each other's strong points and make the diagnosis more accurate, so they are often used as indicators to assess the risk of ovarian cancer in clinic.
Brief introduction of ovarian cancer
If ovarian or fallopian tube cells grow out of control, cancer will form, collectively known as ovarian cancer.
The ovary is composed of three kinds of cells, which will develop into different types of ovarian tumors. Among them, epithelial ovarian tumors are caused by canceration of cells covering the ovary, ovarian germ cell tumors come from eggs, and stromal tumors come from interstitial cells that maintain ovarian structure.
Epithelial ovarian tumor is the most common type, including serous carcinoma, clear cell carcinoma, mucinous carcinoma, primary peritoneal carcinoma (from fallopian tube cells) _ fallopian tube carcinoma and many other types.
According to the data of National Cancer Center, in 20 18 years, the number of new cases of ovarian cancer is expected to be 52 1000, and 22,500 cases will die.
Although the incidence rate is not too high, the harm of ovarian cancer is not small. The main problem is that it is difficult to find in the early stage. Patients with early ovarian cancer may have no symptoms. With the progress of the disease, symptoms such as abdominal mass, abdominal pain and frequent urination and urgency may occur, but these symptoms are not unique to ovarian cancer, and many other diseases may also occur. Therefore, only if the symptoms last for a long time or appear frequently will doctors doubt the possibility of ovarian cancer.